Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei Corporation
The Board of Directors of Calliditas Therapeutics AB (publ) unanimously recommends that the shareholders and holders of American Depositary Shares (“ADS”) of Calliditas Therapeutics AB (publ) (jointly the “Securityholders”) accept the public tender offer by Asahi Kasei Corporation.
Background
This statement is made by the Board of Directors (the “Board”) of Calliditas Therapeutics AB (publ) (“Calliditas” or the “Company”) pursuant to section II.19 of the Nasdaq Stockholm takeover rules (“Section II.19”) and Regulation 14D under the Securities Exchange Act of 1934, as amended (together with Section II.19, the “Takeover Rules”).
